Increased surface expression of MHC-class I and CD54 was also seen when well-differentiated HCC (HepG2) were treated with IL-2 stimulated primary NK cells and sNK cells derived supernatants (Figure 3B). The gene discussed is IL2; the disease is hepatocellular carcinoma.